Université Paris-Saclay has adopted the Technion Israel Institute of Technology developed device for the diagnosis of Pulmonary Arterial Hypertension (PAH).

The device called the e-nose, is composed of gold nanoparticles coupled with chemical modules and can detect the rare progressive lung disease by analysing a patient’s breath.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It is expected to pave the way for an appropriate diagnosis of this rare form of high-blood pressure.

"The e-nose is a non-invasive and safe detection method that means general screening of PAH could eventually be made available."

Developed by the Technion Israel Institute of Technology team headed by Professor Hossam Haick, e-nose was originally intended to be used for the diagnosis of cancer.

Doctor Sylvia Cohen-Kaminsky from Université Paris-Saclay proposed for the application of the device for PAH which had similar characteristics as that of cancer.

See Also:

The team has created the international associated lab between Inserm, the Technion, and Université Paris-Sud and had documented and released the proof of concept which validated the detection of PAH using the e-nose.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Kaminsky said: “The gold standard for the diagnosis of PAH is right heart catheterism, which can make the right diagnosis, but it is invasive, risky and unsuitable for widespread screening.

“The e-nose is a non-invasive and safe detection method that means general screening of PAH could eventually be made available.”

Professor Marc Humbert from Université Paris-Sud is heading a large clinical trial sponsored by the public hospital system in Paris, Assistance Publique Hopitaux de Paris to validate the usage of e-nose in the detection of PAH.